Channelopathies

Korean Journal of Pediatrics

Volumn 57, Issue 1, 2014, Pages 1-18

  Kim, June Bum ^a  

^a Seoul Children's Hospital   (South Korea)

Author keywords

Channelopathies; Genetics; Ion channels; Pathophysiology

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ABC TRANSPORTER; AQUAPORIN 2; AQUAPORIN 4; CALCIUM CHANNEL; CHLORIDE CHANNEL; CYCLIC NUCLEOTIDE GATED CHANNEL; GLYCINE RECEPTOR; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ION CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYCYSTIN 2; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 2; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; SULFONYLUREA RECEPTOR 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNINDEXED DRUG;

ALBERS SCHOENBERG DISEASE; BARTTER SYNDROME; CARDIOVASCULAR SYSTEM; CHANNELOPATHY; EATON LAMBERT SYNDROME; ENDOCRINE SYSTEM; GENE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE SYSTEM; KIDNEY POLYCYSTIC DISEASE; MUTATION; MYELOOPTIC NEUROPATHY; MYOTONIA; NEPHROGENIC DIABETES INSIPIDUS; NERVOUS SYSTEM; PARALYSIS; PARANEOPLASTIC NEUROPATHY; PHENOTYPE; RESPIRATORY SYSTEM; REVIEW; URINARY TRACT;

EID: 84892561937     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2014.57.1.1     Document Type: Review

References (100)

1. Ashcroft FM. From molecule to malady. Nature 2006;440:440-7.
2. Valverde MA, Cantero-Recasens G, Garcia-Elias A, Jung C, Carreras-Sureda A, Vicente R. Ion channels in asthma. J Biol Chem 2011; 286:32877-82.
3. Saito YA, Strege PR, Tester DJ, Locke GR, III, Talley NJ, Bernard CE, et al. Sodium channel mutation in the irritable bowel syndrome: Evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol 2009;296:G211-8.
4. Hille B. Ion Channels of Excitable Membranes, 3rd ed. Massachusetts: Sinauer Associates, 2001.
5. Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, et al. Molecular diversity of K+ channels. Ann N Y Acad Sci 1999; 868:233-85.
6. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85.
7. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999;79:1317-72.
8. Song YW, Kim SJ, Heo TH, Kim MH, Kim JB. Normokalemic periodic paralysis is not a distinct disease. Muscle Nerve 2012;46:914-6.
9. Tricarico D, Camerino DC. Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. Front Pharmacol 2011;2:8.
10. Kim JB, Kim MH, Lee SJ, Kim DJ, Lee BC. The genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis. J Korean Med Sci 2007;22:946-51.
11. Kil TH, Kim JB. Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the CACNA1S gene in a patient with hypokalemic periodic paralysis. Eur J Paediatr Neurol 2010;14: 278-81.
12. Levitt LP, Rose LI, Dawson DM. Hypokalemic periodic paralysis with arrhythmia. N Engl J Med 1972;286:253-4.
13. Wu F, Mi W, Hernández-Ochoa EO, Burns DK, Fu Y, Gray HF, et al. A calcium channel mutant mouse model of hypokalemic periodic paralysis. J Clin Invest 2012;122:4580-91.
14. Jurkat-Rott K, Weber MA, Fauler M, Guo XH, Holzherr BD, Paczulla A, et al. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci U S A 2009;106:4036-41.
15. Tricarico D, Mele A, Liss B, Ashcroft FM, Lundquist AL, Desai RR, et al. Reduced expression of Kir6.2/SUR2A subunits explains KATP deficiency in K+-depleted rats. Neuromuscul Disord 2008;18:74-80.
16. Kim SJ, Lee YJ, Kim JB. Reduced expression and abnormal locali-zation of the KATP channel subunit SUR2A in patients with familial hypokalemic periodic paralysis. Biochem Biophys Res Commun 2010;391:974-8.
17. Puwanant A, Ruff RL. INa and IKir are reduced in Type 1 hypokalemic and thyrotoxic periodic paralysis. Muscle Nerve 2010;42: 315-27.
18. Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG, et al. Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome. Hum Mutat 2006;27:388.
19. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012;22:99-111.
20. Scheffer IE, Zhang YH, Jansen FE, Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev 2009;31:394-400.
21. Huang X, Tian M, Hernandez CC, Hu N, Macdonald RL. The GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome activated NMD and generated a truncated subunit that was partially rescued by aminoglycoside-induced stop codon read-through. Neurobiol Dis 2012;48:115-23.
22. Maljevic S, Krampfl K, Cobilanschi J, Tilgen N, Beyer S, Weber YG, et al. A mutation in the GABAA receptor α1-subunit is associated with absence epilepsy. Ann Neurol 2006;59:983-7.
23. Hernandez CC, Gurba KN, Hu N, Macdonald RL. The GABRA6 mutation, R46W, associated with childhood absence epilepsy, alters α6β2γ2 and α6β2δ GABAA receptor channel gating and expression. J Physiol 2011;589:5857-78.
24. Tanaka M, Olsen RW, Medina MT, Schwartz E, Alonso ME, Duron RM, et al. Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am J Hum Genet 2008;82:1249-61.
25. Tian M, Macdonald RL. The intronic GABRG2 mutation, IVS6+2T→G, associated with childhood absence epilepsy altered subunit mRNA intron splicing, activated nonsense-mediated decay, and produced a stable truncated γ2 subunit. J Neurosci 2012;32:5937-52.
26. Tottene A, Urbani A, Pietrobon D. Role of different voltage-gated Ca2+ channels in cortical spreading depression: specific requirement of P/Q-type Ca2+ channels. Channels (Austin) 2011;5:110-4.
27. Rajakulendran S, Graves TD, Labrum RW, Kotzadimitriou D, Eunson L, Davis MB, et al. Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. J Physiol 2010; 588:1905-13.
28. Unno T, Wakamori M, Koike M, Uchiyama Y, Ishikawa K, Kubota H, et al. Development of Purkinje cell degeneration in a knockin mouse model reveals lysosomal involvement in the pathogenesis of SCA6. Proc Natl Acad Sci U S A 2012;109:17693-8.
29. Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, Licchetta L, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012;44:1188-90.
30. Rodrigues-Pinguet N, Jia L, Li M, Figl A, Klaassen A, Truong A, et al. Five ADNFLE mutations reduce the Ca2+ dependence of the mammalian α4β2 acetylcholine response. J Physiol 2003;550:11-26.
31. Chung SK, Vanbellinghen JF, Mullins JG, Robinson A, Hantke J, Hammond CL, et al. Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci 2010; 30:9612-20.
32. Bockenhauer D, Feather S, Stanescu HC, Bandulik S, Zdebik AA, Reichold M, et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009;360: 1960-70.
33. Scholl UI, Choi M, Liu T, Ramaekers VT, Häusler MG, Grimmer J, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A 2009;106:5842-7.
34. Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 2010;66:671-80.
35. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006;444:894-8.
36. Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep 2013;14:152-63.
37. Curcio-Morelli C, Zhang P, Venugopal B, Charles FA, Browning MF, Cantiello HF, et al. Functional multimerization of mucolipin channel proteins. J Cell Physiol 2010;222:328-35.
38. Amin AS, Tan HL, Wilde AA. Cardiac ion channels in health and disease. Heart Rhythm 2010;7:117-26.
39. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur Heart J 2008;29:1670-80.
40. Wilders R. Cardiac ion channelopathies and the sudden infant death syndrome. ISRN Cardiol 2012;2012:846171.
41. Campuzano O, Beltrán-Alvarez P, Iglesias A, Scornik F, Pérez G, Brugada R. Genetics and cardiac channelopathies. Genet Med 2010; 12:260-7.
42. Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010;86:872-80.
43. Templin C, Ghadri JR, Rougier JS, Baumer A, Kaplan V, Albesa M, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011;32:1077-88.
44. Wilde AA, Brugada R. Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res 2011;108:884-97.
45. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185-91.
46. Biel M, Wahl-Schott C, Michalakis S, Zong X. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev 2009;89:847-85.
47. Duhme N, Schweizer PA, Thomas D, Becker R, Schröter J, Barends TR, et al. Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart J 2013;34:2768-75.
48. Ueda K, Hirano Y, Higashiuesato Y, Aizawa Y, Hayashi T, Inagaki N, et al. Role of HCN4 channel in preventing ventricular arrhythmia. J Hum Genet 2009;54:115-21.
49. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005;42:863-70.
50. van der Werf C, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside. Heart 2013;99:497-504.
51. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 2007;335:1255-9.
52. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment stra-tegies. Respir Care 2009;54:595-605.
53. Sweeney M, McDaniel SS, Platoshyn O, Zhang S, Yu Y, Lapp BR, et al. Role of capacitative Ca2+ entry in bronchial contraction and remodeling. J Appl Physiol 2002;92:1594-602.
54. So SY, Ip M, Lam WK. Calcium channel blockers and asthma. Lung 1986;164:1-16.
55. Xiao JH, Zheng YM, Liao B, Wang YX. Functional role of canonical transient receptor potential 1 and canonical transient receptor potential 3 in normal and asthmatic airway smooth muscle cells. Am J Respir Cell Mol Biol 2010;43:17-25.
56. Sel S, Rost BR, Yildirim AO, Sel B, Kalwa H, Fehrenbach H, et al. Loss of classical transient receptor potential 6 channel reduces allergic airway response. Clin Exp Allergy 2008;38:1548-58.
57. Vennekens R, Olausson J, Meissner M, Bloch W, Mathar I, Philipp SE, et al. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol 2007;8:312-20.
58. Lee LY, Gu Q. Role of TRPV1 in inflammation-induced airway hypersensitivity. Curr Opin Pharmacol 2009;9:243-9.
59. Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D'Amours M, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A 2009;106:9099-104.
60. Akhabir L, Sandford AJ. Genome-wide association studies for discovery of genes involved in asthma. Respirology 2011;16:396-406.
61. Mahn K, Hirst SJ, Ying S, Holt MR, Lavender P, Ojo OO, et al. Diminished sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression contributes to airway remodeling in bronchial asthma. Proc Natl Acad Sci U S A 2009;106:10775-80.
62. Webster R, Maxwell S, Spearman H, Tai K, Beckstein O, Sansom M, et al. A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance. Brain 2012;135: 1070-80.
63. Pyo JY, Joh DH, Park JS, Lee SJ, Lee H, Kim W, et al. Ventricular tachyarrhythmias in a patient with Andersen-Tawil syndrome. Korean Circ J 2013;43:62-5.
64. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 1989;54:87-143.
65. Vivaudou M, Moreau CJ, Terzic A. Structure and function of ATP-sensitive K+ channels. In: Kew J, Davies C, editors. Ion channels: from structure to function. 1st ed. Oxford: Oxford University Press, 2009:454-73.
66. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-66.
67. Kong JH, Kim JB. Transient neonatal diabetes mellitus caused by a de novo ABCC8 gene mutation. Korean J Pediatr 2011;54:179-82.
68. Koster JC, Permutt MA, Nichols CG. Diabetes and insulin secretion: the ATP-sensitive K+ channel (KATP) connection. Diabetes 2005; 54:3065-72.
69. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005;115:2047-58.
70. Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010;140:88-98.
71. Ruff RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology 1999;53:1556-63.
72. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012;109:2533-8.
73. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008;42:19-29.
74. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Sta-hlhut M, et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-53.
75. Riepe FG. Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res 2009;72:1-9.
76. Butterworth MB. Regulation of the epithelial sodium channel (ENaC) by membrane trafficking. Biochim Biophys Acta 2010;1802:1166-77.
77. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013;34:278-301.
78. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol 2006;104:73-80.
79. Schlingmann KP, Waldegger S, Konrad M, Chubanov V, Gudermann T. TRPM6 and TRPM7-Gatekeepers of human magnesium metabolism. Biochim Biophys Acta 2007;1772:813-21.
80. Dryer SE, Reiser J. TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol 2010;299:F689-701.
81. Miyakawa A, Ibarra C, Malmersjö S, Aperia A, Wiklund P, Uhlén P. Intracellular calcium release modulates polycystin-2 trafficking. BMC Nephrol 2013;14:34.
82. Zaika O, Mamenko M, Berrout J, Boukelmoune N, O'Neil RG, Po-chynyuk O. TRPV4 dysfunction promotes renal cystogenesis in autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2013;24:604-16.
83. Kleopa KA. Autoimmune channelopathies of the nervous system. Curr Neuropharmacol 2011;9:458-67.
84. Vincent A. Developments in autoimmune channelopathies. Auto-immun Rev 2013;12:678-81.
85. Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013;12:918-23.
86. Winston N, Vernino S. Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol 2010;23:514-8.
87. Titulaer MJ, Lang B, Verschuuren J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098-107.
88. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759-72.
89. Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, et al. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 2004;56:440-4.
90. Liewluck T, Klein CJ, Jones LK Jr. Cramp-fasciculation syndrome in patients with and without neural autoantibodies. Muscle Nerve 2013, doi: 10.1002/mus.23935
91. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
92. Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012;259:622-9.
93. Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 2012;44:1519-30.
94. Jensen CJ, Massie A, De Keyser J. Immune Players in the CNS: The Astrocyte. J Neuroimmune Pharmacol 2013;8:824-39.
95. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 2009;9:132-5.
96. Pedersen SF, Stock C. Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res 2013;73:1658-61.
97. Morelli MB, Liberati S, Amantini C, Nabissi M, Santoni M, Farfariello V, et al. Expression and function of the transient receptor potential ion channel family in the hematologic malignancies. Curr Mol Pharmacol 2013, doi: 10.2174/1874467211 3069990030
98. Imbrici P, Camerino DC, Tricarico D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet 2013;4:76.
99. Skaper SD. Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets 2011;10:44-56.
100. Bollimuntha S, Selvaraj S, Singh BB. Emerging roles of canonical TRP channels in neuronal function. Adv Exp Med Biol 2011;704:573-93.